Lupin 2024

Vantrela ER

Teva gets FDA’s OK for Vantrela ER

Teva gets FDA’s OK for Vantrela ER

JERUSALEM, Israel — Teva Pharmaceutical Industries Ltd. has received Food and Drug Administration approval for Vantrela ER, an opioid pain medication with Teva’s abuse deterrence technology. Vantrela ER (hydrocodone bitartrate extended-release tablets, CII) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which other treatment options

PP_1170x120_10-25-21